Daily Piece: July 31st Updates to ADA Living Standards

Three important updates to the ADA “Living” Standard to know about are the incorporation of:

  1. International consensus report on continuous glucose monitoring and time in range (which tells a much more thorough story than A1c) (Standards 6 and 7)
  2. Results of Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial which reveals reduction in cardiovascular events with dulaglutide in adults with type 2 diabetes with or without existing cardiovascular disease (now that is exciting!!!) (Standards 9 and 10)
  3. FDA’a approval of liraglutide in pediatric patients with type 2 diabetes, and publication detailing drug’s effects in this population (a game changer as we now have more metformin as non-insulin options in pediatrics) (Standards 9 and 13)

Boy, such exciting updates! To review the updated standards for more details, please click below.

https://care.diabetesjournals.org/content/42/Supplement_1?utm_source=living-standards-update-073119&utm_medium=email&utm_content=diabetes-care-website-2&utm_campaign=PRO&s_src=email&s_subsrc=649516

Image result for updates
This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#ADA #updates #CGM #dulaglutide #pediatrics #liraglutide

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram ReecesPiecesDI.

Leave a Reply

Your email address will not be published. Required fields are marked *